XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

Inclusion Criteria

• •1. Diagnosed as colorectal adenocarcinoma by histopathology and/or cytology.
• •2. Patients could not receive surgical resection.
• •3. Never received chemotherapy or radiotherapy.
• •4. According to the RECIST v1.1 guide, at least 1 lesions (never received radiotherapy),accurately measured by computed tomography (CT) or magnetic resonance imaging (MRI) (intravenous contrast agent as the first choice),the longest diameter was more than 10mm (except for the lymph nodes, the short axis of the lymph nodes must be more than 15mm), repeated measurement.
• •5. Eastern Cooperative Oncology Group Performance Status(ECOG PS):0-1 score
• •6. The main organs function is normal, which meets the following requirements. (1) Blood routine examination,(no blood transfusion within 14 days).
• •1. Hemoglobin(HB)≥90g/L;
• •2. Absolute neutrophil count (ANC) ≥1.5×10\^9/L;
• •3. Blood platelet (PLT)≥80×10\^9/L; (2) Biochemical examination should comply with the following criteria:
• •<!-- -->
• •1. Bilirubin(BIL) \<1.5 times of the upper limit of normal value (ULN)
• •2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\<2.5\*ULN (liver metastasis ALT and AST\<5\*ULN).
• •3. Serum Cr≤1\*ULN, creatinine clearance rate≥50ml/min (Cockcroft-Gault formula)
• •7. The expected survival time more than 3 months;
• •8. The physicians plan to use XELOX + bevacizumab chemotherapy or XELIRI+bevacizumab chemotherapy.
• •9. Patients voluntarily joined the study and signed informed consent form (ICF).
• •10. Child bearing age women must undergo a negative pregnancy test (serum or urine) within 7 days ,and voluntarily adopt appropriate methods for contraception from the period of under observation and within 8 weeks of the last time they are given the drug; As for men, it is necessary to receive surgical sterilization, or agree to adopt appropriate methods for contraception from the period of under observation and within 8 weeks of the last time they are given the drug.